Summary
12.71 0.33(2.66%)10/04/2024
UroGen Pharma Ltd (URGN)
UroGen Pharma Ltd (URGN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.58 | -1.20 | -9.12 | -19.91 | -6.48 | -5.01 | -44.88 | -9.08 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 12.71 | |
| Open | 12.49 | |
| High | 12.89 | |
| Low | 12.43 | |
| Volume | 221,745 | |
| Change | 0.32 | |
| Change % | 2.58 | |
| Avg Volume (20 Days) | 458,110 | |
| Volume/Avg Volume (20 Days) Ratio | 0.48 | |
| 52 Week Range | 10.60 - 20.70 | |
| Price vs 52 Week High | -38.60% | |
| Price vs 52 Week Low | 19.91% | |
| Range | 1.76 | |
| Gap Up/Down | -0.12 | |
Fundamentals | ||
| Market Capitalization (Mln) | 537 | |
| EBIDTA | -81,143,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 39.80 | |
| Book Value | 1.4080 | |
| Earnings Per Share | -5.0680 | |
| EPS Estimate Current Quarter | -1.2900 | |
| EPS Estimate Next Quarter | -1.2900 | |
| EPS Estimate Current Year | -4.8100 | |
| EPS Estimate Next Year | -3.3700 | |
| Diluted EPS (TTM) | -5.0680 | |
| Revenues | ||
| Profit Marging | -2.8341 | |
| Operating Marging (TTM) | -2.5012 | |
| Return on asset (TTM) | -0.4537 | |
| Return on equity (TTM) | -1.4848 | |
| Revenue TTM | 39,834,000 | |
| Revenue per share TTM | 1.7880 | |
| Quarterly Revenue Growth (YOY) | 2.2800 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 10,790,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 7.8130 | |
| Revenue Enterprise Value | 3.5348 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 22,420,300 | |
| Shares Float | 18,871,188 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 8.63 | |
| Institutions (%) | 78.04 | |
08/29 08:00 EST - businesswire.com
UroGen Pharma to Present at Upcoming Investor Conferences
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in fireside chats at the following investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference – September 9-11th, 2024 Fireside Chat: September 9th, 2024 at 9:00am ET Location: New York, NY Webcast Registration Link: Here 2024 C.
UroGen Pharma to Present at Upcoming Investor Conferences
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in fireside chats at the following investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference – September 9-11th, 2024 Fireside Chat: September 9th, 2024 at 9:00am ET Location: New York, NY Webcast Registration Link: Here 2024 C.
08/13 15:05 EST - seekingalpha.com
UroGen Pharma Ltd. (URGN) Q2 2024 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN ) Q2 2024 Earnings Call August 13, 2024 10:00 AM ET Company Participants Vincent Perrone - Head, Investor Relations Liz Barrett - President and Chief Executive Officer Mark Schoenberg - Chief Medical Officer David Lin - Chief Commercial Officer Dong Kim - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen Raghuram Selvaraju - H.C.
UroGen Pharma Ltd. (URGN) Q2 2024 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN ) Q2 2024 Earnings Call August 13, 2024 10:00 AM ET Company Participants Vincent Perrone - Head, Investor Relations Liz Barrett - President and Chief Executive Officer Mark Schoenberg - Chief Medical Officer David Lin - Chief Commercial Officer Dong Kim - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen Raghuram Selvaraju - H.C.
08/13 10:16 EST - zacks.com
Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $1.03 per share a year ago.
Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $1.03 per share a year ago.
08/02 10:56 EST - zacks.com
Does Urogen Pharma (URGN) Have the Potential to Rally 171.05% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 171.1% in Urogen Pharma (URGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Urogen Pharma (URGN) Have the Potential to Rally 171.05% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 171.1% in Urogen Pharma (URGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
08/01 11:05 EST - zacks.com
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
Urogen Pharma (URGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
Urogen Pharma (URGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/17 10:56 EST - zacks.com
Wall Street Analysts See a 149.01% Upside in Urogen Pharma (URGN): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 149% in Urogen Pharma (URGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 149.01% Upside in Urogen Pharma (URGN): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 149% in Urogen Pharma (URGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
06/17 22:51 EST - businesswire.com
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ordinary share, and, to certain investors in lieu of issuing ordinary shares, pre-funded warrants to purchase 1,142,857 ordinary shares at a purchase price of $17.499 per.
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ordinary share, and, to certain investors in lieu of issuing ordinary shares, pre-funded warrants to purchase 1,142,857 ordinary shares at a purchase price of $17.499 per.
06/17 16:46 EST - globenewswire.com
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell its ordinary shares and pre-funded warrants. In connection with the proposed offering, UroGen also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of ordinary shares (including those underlying pre-funded warrants) offered in the public offering. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. All of the ordinary shares and pre-funded warrants to be sold in the proposed offering will be offered by UroGen.
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell its ordinary shares and pre-funded warrants. In connection with the proposed offering, UroGen also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of ordinary shares (including those underlying pre-funded warrants) offered in the public offering. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. All of the ordinary shares and pre-funded warrants to be sold in the proposed offering will be offered by UroGen.
06/17 06:01 EST - zacks.com
Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
Urogen Pharma (URGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
Urogen Pharma (URGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
06/13 10:54 EST - businesswire.com
Uber Advertising Announces Exclusive Partnership with T-Mobile Advertising Solutions
SAN FRANCISCO & BELLEVUE, Wash.--(BUSINESS WIRE)--Today, Uber's advertising division announced an exclusive partnership with T-Mobile Advertising Solutions and its rideshare media network – Octopus Interactive – which features the largest national network of interactive video screens inside rideshare vehicles. Through this partnership, Uber will leverage a portion of T-Mobile's rideshare inventory to expand Uber's JourneyTV offering to over 50,000 vehicles across the US this year, providing adv.
Uber Advertising Announces Exclusive Partnership with T-Mobile Advertising Solutions
SAN FRANCISCO & BELLEVUE, Wash.--(BUSINESS WIRE)--Today, Uber's advertising division announced an exclusive partnership with T-Mobile Advertising Solutions and its rideshare media network – Octopus Interactive – which features the largest national network of interactive video screens inside rideshare vehicles. Through this partnership, Uber will leverage a portion of T-Mobile's rideshare inventory to expand Uber's JourneyTV offering to over 50,000 vehicles across the US this year, providing adv.
06/13 10:49 EST - businesswire.com
AscellaHealth Chairman and President Bill Oldham Named 2024 Philadelphia Titan 100
BERWYN, Pa.--(BUSINESS WIRE)--Bill Oldham, chairman and president, AscellaHealth, honored as a 2024 Philadelphia Titan 100.
AscellaHealth Chairman and President Bill Oldham Named 2024 Philadelphia Titan 100
BERWYN, Pa.--(BUSINESS WIRE)--Bill Oldham, chairman and president, AscellaHealth, honored as a 2024 Philadelphia Titan 100.
06/13 10:45 EST - businesswire.com
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced 82.3% (95% CI, 75.9%, 87.1%) 12-month duration of response (DOR) data by Kaplan-Meier estimate (n=108) from its Phase 3 ENVISION trial in patients who achieved complete response (CR) at three months after the first instillation of investigational drug UGN-102 (mitomycin) for intravesical so.
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced 82.3% (95% CI, 75.9%, 87.1%) 12-month duration of response (DOR) data by Kaplan-Meier estimate (n=108) from its Phase 3 ENVISION trial in patients who achieved complete response (CR) at three months after the first instillation of investigational drug UGN-102 (mitomycin) for intravesical so.
06/07 08:00 EST - businesswire.com
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) and an option (“Option”) to 15 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen's first ap.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) and an option (“Option”) to 15 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen's first ap.
06/06 08:00 EST - businesswire.com
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today shared additional details about the upcoming ENVISION virtual data event on Thursday, June 13, 2024, at 11:00 a.m. Eastern Time. The event will focus on UGN-102 (mitomycin) for intravesical solution for patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). UroGe.
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today shared additional details about the upcoming ENVISION virtual data event on Thursday, June 13, 2024, at 11:00 a.m. Eastern Time. The event will focus on UGN-102 (mitomycin) for intravesical solution for patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). UroGe.
06/05 08:00 EST - businesswire.com
UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will participate in a fireside chat at the 45th Annual Goldman Sachs Global Healthcare Conference to take place June 10-13, 2024. Goldman Sachs 45th Annual Healthcare Conference Date/ time: June 11, 2024 at 3:20 PM ET Format: Fireside Chat Location: Miami, FL Webcast Li.
UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will participate in a fireside chat at the 45th Annual Goldman Sachs Global Healthcare Conference to take place June 10-13, 2024. Goldman Sachs 45th Annual Healthcare Conference Date/ time: June 11, 2024 at 3:20 PM ET Format: Fireside Chat Location: Miami, FL Webcast Li.
06/03 08:00 EST - businesswire.com
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that David Lin will join UroGen as its Chief Commercial Officer and member of the Executive Leadership Team. In this role, David will be spearheading UroGen's commercial strategy, including preparation for the potential launch of our lead pipeline candidate UGN-102, if approved, and driving.
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that David Lin will join UroGen as its Chief Commercial Officer and member of the Executive Leadership Team. In this role, David will be spearheading UroGen's commercial strategy, including preparation for the potential launch of our lead pipeline candidate UGN-102, if approved, and driving.
05/22 08:00 EST - businesswire.com
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will participate in a virtual fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit on Tuesday, May 28, 2024 at 3:20 PM ET. A live webcast of the fireside chat can be accessed by visiting the Events and Presentations Section of the Company's website: https.
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will participate in a virtual fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit on Tuesday, May 28, 2024 at 3:20 PM ET. A live webcast of the fireside chat can be accessed by visiting the Events and Presentations Section of the Company's website: https.
05/13 18:30 EST - seekingalpha.com
UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN ) Q1 2024 Earnings Conference Call May 13, 2024 10:00 AM ET Company Participants Vincent Perrone - Head of IR Elizabeth Barrett - President & CEO Mark Schoenberg - Chief Medical Officer Don Kim - CFO Jeff Bova - Chief Commercial Officer Conference Call Participants Tara Bancroft - TD Cowen Raghuram Selvaraju - H.C.
UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN ) Q1 2024 Earnings Conference Call May 13, 2024 10:00 AM ET Company Participants Vincent Perrone - Head of IR Elizabeth Barrett - President & CEO Mark Schoenberg - Chief Medical Officer Don Kim - CFO Jeff Bova - Chief Commercial Officer Conference Call Participants Tara Bancroft - TD Cowen Raghuram Selvaraju - H.C.
05/13 08:00 EST - businesswire.com
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent developments. “In 2024 to date, UroGen has made excellent progress in both our commercial business and pipeline of innovative products designed to treat urothelial and specialty cancers,” s.
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent developments. “In 2024 to date, UroGen has made excellent progress in both our commercial business and pipeline of innovative products designed to treat urothelial and specialty cancers,” s.
05/07 08:00 EST - businesswire.com
UroGen Pharma to Participate at Upcoming Investor Conferences
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in May: Citizens JMP Life Sciences Conference – May 14, 2024 Fireside Chat: May 14, 2024 at 10:00am ET Location: New York, NY Webcast Registration Link: Here H.C. Wainwright BioConnect Conference – May 20, 2024 Fireside Chat: M.
UroGen Pharma to Participate at Upcoming Investor Conferences
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in May: Citizens JMP Life Sciences Conference – May 14, 2024 Fireside Chat: May 14, 2024 at 10:00am ET Location: New York, NY Webcast Registration Link: Here H.C. Wainwright BioConnect Conference – May 20, 2024 Fireside Chat: M.